Earnings Call Summary | Avinger(AVGR.US) Q2 2024 Earnings Conference
Earnings Call Summary | Avinger(AVGR.US) Q2 2024 Earnings Conference
Operating expenses in Q2 2024 were $4.5 million, reduced from $5.4 million in Q1 2024 due to a significant headcount reduction.The following is a summary of the Avinger, Inc. (AVGR) Q2 2024 Earnings Call Transcript:
以下是Avinger股份有限公司（AVGR）2024年第二季度業績會交流摘要：
Financial Performance:
金融業績：
Avinger reported a total revenue of $1.8 million for Q2 2024, compared to $1.9 million in Q1 2024 and $2 million in Q2 2023.
Gross margin was 20% in Q2 2024, reflecting a decrease from 30% in Q2 2023, primarily due to lower production activity.
Operating expenses in Q2 2024 were $4.5 million, reduced from $5.4 million in Q1 2024 due to a significant headcount reduction.
Net loss for the quarter was $4.4 million, slightly higher than the $4.2 million loss in Q2 2023.
Avinger於2024年Q2實現總營業收入180萬美元，相比2024年Q1的190萬美元和2023年Q2的200萬美元均有所下降。
2024年Q2毛利率爲20％，較2023年Q2的30％有所下降，主要原因是生產活動減少。
2024年Q2營業費用爲450萬美元，較2024年Q1的540萬美元減少，主要是由於人員減少。
本季度淨虧損爲440萬美元，略高於2023年Q2的420萬美元虧損。
Business Progress:
業務進展：
Introduced strategic partnership with Zylox-Tonbridge, aimed at entering the Greater China market with Avinger's peripheral products.
Secured a public offering providing up to $24 million in growth financing.
Advanced the development of a proprietary image-guided coronary CTO crossing device, expecting to file an IDE application with the FDA soon.
Launched new Pantheris LV atherectomy catheter in the peripheral vascular space.
與Zylox-Tonbridge建立了戰略合作伙伴關係，旨在使用Avinger的外圍設備進入大中華市場。
獲得公開發行，提供高達2400萬美元的成長融資。
推進了具有專有圖像引導的冠脈CTO穿越設備的研發工作，預計不久將向FDA申請IDE。
在外周血管領域推出了新的Pantheris LV切除導管。
Opportunities:
機會：
Partnership with Zylox-Tonbridge opens a pathway to the Greater China market, which could significantly boost the revenue base post-2025.
The Coronary CTO crossing device leverages existing high-value reimbursement codes, enhancing market competitiveness.
與Zylox-Tonbridge的合作伙伴關係爲進入大中華市場打開了通路，這可能在2025年後顯着提升收入基礎。
冠狀動脈CTO穿越設備利用現有的高價值報銷代碼，提高了市場競爭力。
Risks:
風險：
Decline in revenue resulting from the reduction in field sales head count, although seen as a strategic move towards more profitable ventures.
銷售現場人員減少導致收入下降，雖然被視爲走向更具利潤性的決策。
More details: Avinger IR
更多細節請參見Avinger IR。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
